{"name":"Qilu Pharmaceutical Co., Ltd.","slug":"qilu-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"qilu.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":25,"colorKey":"immunology","drugs":[{"name":"CEND-1","genericName":"CEND-1","slug":"cend-1","indication":"Other","status":"phase_2"},{"name":"QL1012","genericName":"QL1012","slug":"ql1012","indication":"unknown","status":"phase_3"},{"name":"QLC5508","genericName":"QLC5508","slug":"qlc5508","indication":"unknown","status":"phase_3"},{"name":"QLC7401","genericName":"QLC7401","slug":"qlc7401","indication":"Other","status":"phase_3"},{"name":"QLS1128","genericName":"QLS1128","slug":"qls1128","indication":"Other","status":"phase_3"},{"name":"US Neulasta","genericName":"US Neulasta","slug":"us-neulasta","indication":"Other","status":"phase_1"},{"name":"DARZALEX FASPRO®","genericName":"DARZALEX FASPRO®","slug":"darzalex-faspro","indication":"Other","status":"marketed"},{"name":"ESG401","genericName":"ESG401","slug":"esg401","indication":"Other","status":"phase_3"},{"name":"GM1","genericName":"GM1","slug":"gm1","indication":"Acute ischemic stroke","status":"phase_3"},{"name":"Monosialoganglioside","genericName":"Monosialoganglioside","slug":"monosialoganglioside","indication":"Other","status":"phase_3"},{"name":"Placebo for QLS31905","genericName":"Placebo for QLS31905","slug":"placebo-for-qls31905","indication":"Other","status":"phase_3"},{"name":"Prolia®","genericName":"Prolia®","slug":"prolia","indication":"Other","status":"marketed"},{"name":"QL-007 tablet","genericName":"QL-007 tablet","slug":"ql-007-tablet","indication":"Other","status":"phase_2"},{"name":"QL1207H injection","genericName":"QL1207H injection","slug":"ql1207h-injection","indication":"Other","status":"phase_3"},{"name":"QL2108 injection","genericName":"QL2108 injection","slug":"ql2108-injection","indication":"Other","status":"phase_3"},{"name":"QLG1091","genericName":"QLG1091","slug":"qlg1091","indication":"unknown","status":"phase_3"},{"name":"QLG2128","genericName":"QLG2128","slug":"qlg2128","indication":"Other","status":"phase_3"},{"name":"QLM3004 Concentration 1","genericName":"QLM3004 Concentration 1","slug":"qlm3004-concentration-1","indication":"Phase 3 clinical trials are being conducted for QLM3004 Concentration 1, but the specific indications are not publicly available.","status":"phase_3"},{"name":"QLM3004 Concentration 2","genericName":"QLM3004 Concentration 2","slug":"qlm3004-concentration-2","indication":"Other","status":"phase_3"},{"name":"QLM3004 Concentration 3","genericName":"QLM3004 Concentration 3","slug":"qlm3004-concentration-3","indication":"unknown","status":"phase_3"},{"name":"QLS5132; Platinum; Bevacizumab","genericName":"QLS5132; Platinum; Bevacizumab","slug":"qls5132-platinum-bevacizumab","indication":"Other","status":"phase_1"},{"name":"Tilesizumab","genericName":"Tilesizumab","slug":"tilesizumab","indication":"Other","status":"phase_3"},{"name":"Xiidra","genericName":"Xiidra","slug":"xiidra","indication":"Tear film insufficiency","status":"marketed"},{"name":"placebo for QL1604","genericName":"placebo for QL1604","slug":"placebo-for-ql1604","indication":"Treatment of symptoms in clinical trials","status":"phase_3"},{"name":"platinum, IV infusion","genericName":"platinum, IV infusion","slug":"platinum-iv-infusion","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"QLS32015","genericName":"QLS32015","slug":"qls32015","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QL1701","genericName":"QL1701","slug":"ql1701","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Dose 1 of QLS1410","genericName":"Dose 1 of QLS1410","slug":"dose-1-of-qls1410","indication":"Type 2 diabetes","status":"phase_2"},{"name":"QL0911","genericName":"QL0911","slug":"ql0911","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QL1203","genericName":"QL1203","slug":"ql1203","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QL1206","genericName":"QL1206","slug":"ql1206","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QL1209","genericName":"QL1209","slug":"ql1209","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QL2107","genericName":"QL2107","slug":"ql2107","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QL2109","genericName":"QL2109","slug":"ql2109","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QLG1080","genericName":"QLG1080","slug":"qlg1080","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"QL1604","genericName":"QL1604","slug":"ql1604","indication":"Type 2 diabetes","status":"phase_3"},{"name":"QLS31905","genericName":"QLS31905","slug":"qls31905","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"WX-0593 Tablets","genericName":"WX-0593 Tablets","slug":"wx-0593-tablets","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CAPEOX/Capecitabine","genericName":"CAPEOX/Capecitabine","slug":"capeox-capecitabine","indication":"Metastatic colorectal cancer (in combination with oxaliplatin as CAPEOX)","status":"phase_3"},{"name":"MHB088C for Injection","genericName":"MHB088C for Injection","slug":"mhb088c-for-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"QL0605(PEG-rhG-CSF)","genericName":"QL0605(PEG-rhG-CSF)","slug":"ql0605-peg-rhg-csf","indication":"Chemotherapy-induced neutropenia (CIN) in cancer patients","status":"marketed"},{"name":"QL1101","genericName":"QL1101","slug":"ql1101","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"QLM2010 for injection；dexamethasone","genericName":"QLM2010 for injection；dexamethasone","slug":"qlm2010-for-injection-dexamethasone","indication":"Multiple myeloma","status":"phase_3"},{"name":"VB4-845 Injection","genericName":"VB4-845 Injection","slug":"vb4-845-injection","indication":"HER2-positive gastric cancer","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Ceftazidime-avibactam","genericName":"Ceftazidime-avibactam","slug":"ceftazidime-avibactam","indication":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","status":"marketed"},{"name":"Meropenem and Pralurbactam","genericName":"Meropenem and Pralurbactam","slug":"meropenem-and-pralurbactam","indication":"Complicated intra-abdominal infections","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Olanzapine-samidorphan；","genericName":"Olanzapine-samidorphan；","slug":"olanzapine-samidorphan","indication":"Treatment of schizophrenia","status":"phase_3"},{"name":"Tafamidis Meglumine Soft Capsules","genericName":"Tafamidis Meglumine Soft Capsules","slug":"tafamidis-meglumine-soft-capsules","indication":"Transthyretin amyloidosis (ATTR amyloidosis), including hereditary ATTR (hATTR) with polyneuropathy","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"QLM3003","genericName":"QLM3003","slug":"qlm3003","indication":"Hypertension","status":"phase_3"},{"name":"pALG/ rATG","genericName":"pALG/ rATG","slug":"palg-ratg","indication":"Prevention of organ rejection in kidney transplant patients","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"rare","drugs":[{"name":"Romiplostim N01","genericName":"Romiplostim N01","slug":"romiplostim-n01","indication":"Immune thrombocytopenia","status":"phase_3"},{"name":"Voclosporin（QL1074）","genericName":"Voclosporin（QL1074）","slug":"voclosporin-ql1074","indication":"Lupus nephritis","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"Tezspire","genericName":"Tezspire","slug":"tezspire","indication":"Severe asthma","status":"marketed"},{"name":"tezepelumab (Arm1&Arm2)","genericName":"tezepelumab (Arm1&Arm2)","slug":"tezepelumab-arm1-arm2","indication":"Severe asthma with an eosinophilic phenotype","status":"phase_3"}]}],"pipeline":[{"name":"QLS32015","genericName":"QLS32015","slug":"qls32015","phase":"phase_3","mechanism":"QLS32015 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CEND-1","genericName":"CEND-1","slug":"cend-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"QL1701","genericName":"QL1701","slug":"ql1701","phase":"phase_3","mechanism":"QL1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Dose 1 of QLS1410","genericName":"Dose 1 of QLS1410","slug":"dose-1-of-qls1410","phase":"phase_2","mechanism":"QLS1410 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QL0911","genericName":"QL0911","slug":"ql0911","phase":"phase_3","mechanism":"QL0911 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QL1012","genericName":"QL1012","slug":"ql1012","phase":"phase_3","mechanism":"QL1012 is a small molecule that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"QL1203","genericName":"QL1203","slug":"ql1203","phase":"phase_3","mechanism":"QL1203 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QL1206","genericName":"QL1206","slug":"ql1206","phase":"phase_3","mechanism":"QL1206 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QL1209","genericName":"QL1209","slug":"ql1209","phase":"phase_3","mechanism":"QL1209 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QL2107","genericName":"QL2107","slug":"ql2107","phase":"phase_3","mechanism":"QL2107 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QL2109","genericName":"QL2109","slug":"ql2109","phase":"phase_3","mechanism":"QL2109 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QLC5508","genericName":"QLC5508","slug":"qlc5508","phase":"phase_3","mechanism":"QLC5508 is a small molecule drug that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"QLC7401","genericName":"QLC7401","slug":"qlc7401","phase":"phase_3","mechanism":"QLC7401 is a small-molecule inhibitor that targets specific cellular pathways involved in disease progression.","indications":[],"catalyst":""},{"name":"QLG1080","genericName":"QLG1080","slug":"qlg1080","phase":"phase_3","mechanism":"QLG1080 is a GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"QLS1128","genericName":"QLS1128","slug":"qls1128","phase":"phase_3","mechanism":"QLS1128 is a small molecule inhibitor targeting a specific molecular pathway in phase 3 development by Qilu Pharmaceutical.","indications":[],"catalyst":""},{"name":"US Neulasta","genericName":"US Neulasta","slug":"us-neulasta","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"WX-0593 Tablets","genericName":"WX-0593 Tablets","slug":"wx-0593-tablets","phase":"phase_3","mechanism":"WX-0593 Tablets is a small molecule drug that targets the HIF-1α pathway.","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"CAPEOX/Capecitabine","genericName":"CAPEOX/Capecitabine","slug":"capeox-capecitabine","phase":"phase_3","mechanism":"Capecitabine is a prodrug that is converted to fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell division and survival.","indications":["Metastatic colorectal cancer (in combination with oxaliplatin as CAPEOX)","Metastatic breast cancer","Gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"Ceftazidime-avibactam","genericName":"Ceftazidime-avibactam","slug":"ceftazidime-avibactam","phase":"marketed","mechanism":"Ceftazidime-avibactam is a combination of a third-generation cephalosporin antibiotic and a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","indications":["Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","Complicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria","Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)","Aerobic gram-negative bacterial infections in patients with limited treatment options"],"catalyst":""},{"name":"DARZALEX FASPRO®","genericName":"DARZALEX FASPRO®","slug":"darzalex-faspro","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ESG401","genericName":"ESG401","slug":"esg401","phase":"phase_3","mechanism":"ESG401 is an investigational drug in phase 3 development by Qilu Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"GM1","genericName":"GM1","slug":"gm1","phase":"phase_3","mechanism":"GM1 is a monosialotetrahexosylganglioside that promotes neuronal protection and regeneration by enhancing nerve growth factor signaling and reducing neuroinflammation.","indications":["Acute ischemic stroke","Spinal cord injury","Peripheral nerve injury"],"catalyst":""},{"name":"MHB088C for Injection","genericName":"MHB088C for Injection","slug":"mhb088c-for-injection","phase":"phase_3","mechanism":"MHB088C is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"Meropenem and Pralurbactam","genericName":"Meropenem and Pralurbactam","slug":"meropenem-and-pralurbactam","phase":"phase_3","mechanism":"Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria.","indications":["Complicated intra-abdominal infections","Complicated urinary tract infections","Hospital-acquired and ventilator-associated bacterial pneumonia","Infections caused by carbapenem-resistant Enterobacteriaceae (CRE)"],"catalyst":""},{"name":"Monosialoganglioside","genericName":"Monosialoganglioside","slug":"monosialoganglioside","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Olanzapine-samidorphan；","genericName":"Olanzapine-samidorphan；","slug":"olanzapine-samidorphan","phase":"phase_3","mechanism":"Olanzapine-samidorphan is an atypical antipsychotic that combines the antipsychotic effects of olanzapine with the weight loss effects of samidorphan.","indications":["Treatment of schizophrenia"],"catalyst":""},{"name":"Placebo for QLS31905","genericName":"Placebo for QLS31905","slug":"placebo-for-qls31905","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Prolia®","genericName":"Prolia®","slug":"prolia","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"QL-007 tablet","genericName":"QL-007 tablet","slug":"ql-007-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"QL0605(PEG-rhG-CSF)","genericName":"QL0605(PEG-rhG-CSF)","slug":"ql0605-peg-rhg-csf","phase":"marketed","mechanism":"QL0605 is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells to increase white blood cell production.","indications":["Chemotherapy-induced neutropenia (CIN) in cancer patients","Severe chronic neutropenia"],"catalyst":""},{"name":"QL1101","genericName":"QL1101","slug":"ql1101","phase":"phase_3","mechanism":"QL1101 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"QL1207H injection","genericName":"QL1207H injection","slug":"ql1207h-injection","phase":"phase_3","mechanism":"QL1207H injection's mechanism is not publicly available.","indications":[],"catalyst":""},{"name":"QL1604","genericName":"QL1604","slug":"ql1604","phase":"phase_3","mechanism":"QL1604 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QL2108 injection","genericName":"QL2108 injection","slug":"ql2108-injection","phase":"phase_3","mechanism":"QL2108 injection's mechanism is not publicly available.","indications":[],"catalyst":""},{"name":"QLG1091","genericName":"QLG1091","slug":"qlg1091","phase":"phase_3","mechanism":"QLG1091 is a small molecule drug that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"QLG2128","genericName":"QLG2128","slug":"qlg2128","phase":"phase_3","mechanism":"QLG2128 is a small molecule inhibitor targeting a specific molecular pathway relevant to its therapeutic indication.","indications":[],"catalyst":""},{"name":"QLM2010 for injection；dexamethasone","genericName":"QLM2010 for injection；dexamethasone","slug":"qlm2010-for-injection-dexamethasone","phase":"phase_3","mechanism":"Dexamethasone is a corticosteroid that suppresses the immune system and reduces inflammation.","indications":["Multiple myeloma","Hodgkin lymphoma","Non-Hodgkin lymphoma"],"catalyst":""},{"name":"QLM3003","genericName":"QLM3003","slug":"qlm3003","phase":"phase_3","mechanism":"QLM3003 is a small molecule drug that targets the molecular target.","indications":["Hypertension"],"catalyst":""},{"name":"QLM3004 Concentration 1","genericName":"QLM3004 Concentration 1","slug":"qlm3004-concentration-1","phase":"phase_3","mechanism":"QLM3004 Concentration 1 is a drug that targets the molecular target to exert its therapeutic effect.","indications":["Phase 3 clinical trials are being conducted for QLM3004 Concentration 1, but the specific indications are not publicly available."],"catalyst":""},{"name":"QLM3004 Concentration 2","genericName":"QLM3004 Concentration 2","slug":"qlm3004-concentration-2","phase":"phase_3","mechanism":"QLM3004 Concentration 2 is a drug that targets the molecular target to exert its therapeutic effect.","indications":[],"catalyst":""},{"name":"QLM3004 Concentration 3","genericName":"QLM3004 Concentration 3","slug":"qlm3004-concentration-3","phase":"phase_3","mechanism":"QLM3004 Concentration 3 is a drug that works by inhibiting the activity of a specific molecular target.","indications":["unknown"],"catalyst":""},{"name":"QLS31905","genericName":"QLS31905","slug":"qls31905","phase":"phase_3","mechanism":"QLS31905 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"QLS5132; Platinum; Bevacizumab","genericName":"QLS5132; Platinum; Bevacizumab","slug":"qls5132-platinum-bevacizumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Romiplostim N01","genericName":"Romiplostim N01","slug":"romiplostim-n01","phase":"phase_3","mechanism":"Romiplostim N01 is a thrombopoietin receptor agonist that stimulates platelet production.","indications":["Immune thrombocytopenia"],"catalyst":""},{"name":"Tafamidis Meglumine Soft Capsules","genericName":"Tafamidis Meglumine Soft Capsules","slug":"tafamidis-meglumine-soft-capsules","phase":"marketed","mechanism":"Tafamidis stabilizes transthyretin (TTR) protein tetramers, preventing their dissociation and misfolding into amyloid fibrils.","indications":["Transthyretin amyloidosis (ATTR amyloidosis), including hereditary ATTR (hATTR) with polyneuropathy","Wild-type transthyretin amyloidosis (wtATTR)"],"catalyst":""},{"name":"Tezspire","genericName":"Tezspire","slug":"tezspire","phase":"marketed","mechanism":"Thymic stromal lymphopoietin","indications":["Severe asthma"],"catalyst":""},{"name":"Tilesizumab","genericName":"Tilesizumab","slug":"tilesizumab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VB4-845 Injection","genericName":"VB4-845 Injection","slug":"vb4-845-injection","phase":"phase_3","mechanism":"VB4-845 is an anti-VEGF/HER2 bispecific antibody that simultaneously targets vascular endothelial growth factor and human epidermal growth factor receptor 2 to inhibit tumor angiogenesis and block HER2-driven proliferation.","indications":["HER2-positive gastric cancer","HER2-positive breast cancer"],"catalyst":""},{"name":"Voclosporin（QL1074）","genericName":"Voclosporin（QL1074）","slug":"voclosporin-ql1074","phase":"phase_3","mechanism":"Voclosporin is an immunosuppressant that inhibits calcineurin.","indications":["Lupus nephritis"],"catalyst":""},{"name":"Xiidra","genericName":"Xiidra","slug":"xiidra","phase":"marketed","mechanism":"Integrin alpha-L/beta-2, Intercellular adhesion molecule 1","indications":["Tear film insufficiency"],"catalyst":""},{"name":"pALG/ rATG","genericName":"pALG/ rATG","slug":"palg-ratg","phase":"phase_3","mechanism":"pALG and rATG are immunosuppressive drugs that work by inhibiting T-cell activation and proliferation.","indications":["Prevention of organ rejection in kidney transplant patients","Prevention of organ rejection in heart transplant patients"],"catalyst":""},{"name":"placebo for QL1604","genericName":"placebo for QL1604","slug":"placebo-for-ql1604","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":["Treatment of symptoms in clinical trials"],"catalyst":""},{"name":"platinum, IV infusion","genericName":"platinum, IV infusion","slug":"platinum-iv-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"tezepelumab (Arm1&Arm2)","genericName":"tezepelumab (Arm1&Arm2)","slug":"tezepelumab-arm1-arm2","phase":"phase_3","mechanism":"Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), a key cytokine involved in allergic inflammation.","indications":["Severe asthma with an eosinophilic phenotype","Eosinophilic granulomatosis with polyangiitis (EGPA)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQczFaMW1rekJaNmo3bVNnMEJQUmJkSWxPa0tQYmt0T2I3TW5CY1F3VmQ0eWpKcjZDOWVpMnNFQjFkd01ZSkQwRTI4TDRjTF9KMS1VRFNoODBObDE3elJaVTVZN1lvRmMtVl9COU1LX3dZRFlCSkdfcDYxVzNza1dWSU1ZbUoyUlRyZUt6TVZLVTRHYjhhYnozNG91TzhpTUxoVVhUNjlER0huVGFSV3ctb2gtMWE1NU4wSEhBWkJLbkk1amtmbFhVS09UcVF6QXNQR1dFQmczRDhZZENrUVJRVlVPVDNLaDVqZkJ3R2Vvbi1EYjk2R1dyVU1VQkctaTBKM0EycmZPNXVRQnJ3OWpzVFRrUW0wVWxFdWdqLUhhUUtyV0lsSUdHVmh4MS1XMUJTLS02SzJUWl8xdmYwSDE4?oc=5","date":"2026-04-01","type":"regulatory","source":"GlobeNewswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline - GlobeNewswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOWmdoSVZTdVhrc3VVWXlRWHdpT2l0Y3ZYSDBld0V5VlEwX1lEenNkNlBBMEI0X19WVVYxdGFuOWY3VzlLek5zbXBmVGVZMFFHamp5bFB0dmctLWs2RTRUQVM3eXFlLURMMW1kcUdvUllvUDVqRjJQR3ppRzI0SXRsZExxSGdiSFNaeGJpOGpqXzIwSEFUQ0dxdko5RFBUcWJUdHNzaWFiM2FaQ2lGdlBrVTV2V2RVaXgwRDNuX01ZdmFaQ05PNDZqdjRrT2hYaWxyZFk4d1FNUFdkQTlUYUZEU2sxaGh5ZkQxeTlTQ1dsQm1HQUhnX2JHTWE2Yw?oc=5","date":"2026-03-05","type":"trial","source":"Barchart.com","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPckNjZklLLXR5d1BENnNXbGFQenFUQ1NZZUpqRjFJUHYxSWczSWtCcUgtQkxjV28wVzBYYlNQVDc1MXVXR0RRVWhnSEM4clowU3EtMzJJbVUwdjVrSVg4TV8wcmhUX1FVYlpubGs5Z190UWh2ejljX2JyQlN4eE1EUTdKVU5BUmpFOWZFRWhFUzFta2NNTkFSbWVaQlMzRnJ1ZHFJbjNBTy1zU2FseXFYaHBSd2RYcUtZ?oc=5","date":"2026-01-29","type":"deal","source":"Drug Target Review","summary":"Insilico and Qilu partner to create generative AI cardiometabolic drugs - Drug Target Review","headline":"Insilico and Qilu partner to create generative AI cardiometabolic drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPRmtYZ3FyQmJ6WGplejNCTUJ2Q1ktcnc4Sk1TRk5WWGp0STBxUDY0ZFIzMGt6ajJPUmNVcUNkQW9sYmtDb05FZ3FycXhqQXNFVGF1VDJmWHlUa1NkeDZBSVNxaXQ3ZDRpMDVEZVJ5dzV2aFFuNW1HMHFLNjZxR3c4UTZDUQ?oc=5","date":"2026-01-26","type":"deal","source":"Insilico Medicine","summary":"Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies - Insilico Medicine","headline":"Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Car","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOdF8yTXJlNGFhOHdaMGItM3pkRVVxSDJ1XzlUcHFEamVvSXI0dlZHTjB1ZXQwZHM1Y21sVDlJTEt2a3NEQUo5RV95TTctYUtXcDlVNDFabDVMa3F3UFRwU0RRRFl2cTdyc1Z4S3VSeFJyY2pMZWQ1akxaU3dBeS1ETUJuQmlrS2hRSVRldFRLOUdaUUY0dlE3R2I3Uk9HczZEZDFtZXJhVQ?oc=5","date":"2025-11-18","type":"regulatory","source":"BioWorld News","summary":"Henlius, Organon win US FDA approval of first Perjeta biosimilar - BioWorld News","headline":"Henlius, Organon win US FDA approval of first Perjeta biosimilar","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPUzR6YjdKb2xwR3ZSSVFUSHFQOVNoY2ZCQjkxQVpmSUJoOEtiV0VCbzhJa1N2cmlHVVpOei1zRlB2U1EwT3doRnRrb0xpZDV6T01OMWQzeTZORVNmeXBiLUgyQ0VIci1wM2YwbXdKQkNOTUtnVU9sNktXb2h4cjBhZG5MWlBTd21CS0I0NkQ4WGo0RVdVNkVHOVc3Q3NVaEttZjlUVThCOWVpcGJvcFlwOEwtLWxjSE5UN3FpLVZQYVcyU0RPd0VkODk5SkZZUzFqM3Nyb1VGOXVaNnFMNWFTQTZVaWNGdw?oc=5","date":"2025-07-07","type":"deal","source":"prnewswire.com","summary":"Sagent and Qilu Announce Strategic Collaboration to Expand Access to Critical Injectables in U.S. - prnewswire.com","headline":"Sagent and Qilu Announce Strategic Collaboration to Expand Access to Critical Injectables in U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE51RjZwTHY2d1BxLTNTaVJYTERBNkJQUTNHVXA2VlNENUVMSmI5VUk5WHltWHNEVlJyZDVOWDZFMTJPaFJYbnJYbWdQdWQwbUY0ZlhzOEJmN1lMamk4SmxaMlh0bHZuOVE?oc=5","date":"2025-06-03","type":"pipeline","source":"Market.us","summary":"In 2024, powder form dominated the Sodium Gluconate Market with 87.9% share. - Market.us","headline":"In 2024, powder form dominated the Sodium Gluconate Market with 87.9% share.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNb3VxeDB3bWV2Skw5TUw5eXRIUFREakpIaVBiamRlYWlGSmhPSThITHQ0TVpNVnFoT3ktRW91Wk9jdEhQQUtuMTV4eUxxWm9CYkFTTklTWjZVOHpjNnp5OVhuU1E2eVVaZFZabDI2ZVZ5WHppS2Z6RzIteDYycDB4UTBCbnBGQ1FGU3hZazhWalIxaEZaRk16UG1IVTF5a3ZBUEJPY2lxek9GdWFLUHhOU2t2VjBTc2lXdS1FTg?oc=5","date":"2025-05-09","type":"pipeline","source":"Fierce Biotech","summary":"Qilu Pharmaceutical pays $38M upfront for greater China rights to Minghui's ADC - Fierce Biotech","headline":"Qilu Pharmaceutical pays $38M upfront for greater China rights to Minghui's ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPWVBvaGhBNnRBWHVKanEydlFWSzljV3J4RjlTeHZHS0d4SWNVN0kxeHUxWWhuajduWHp6VlZHYzdNeHF5Yy1TakMwR0lxTDh0UjVlOWNPMnRNVFpuVnBFWEFvMUdlbHBZNU92SXZ3eW5XSEtISi14aHdiWjUzcnFYdzRxQS00cjBwd0JkN2ZyLXpPNXF6TTNXeGNkT2xlLUlCT05aWXk5NzQ3eE5PeVZpcl9RNWEzeTRoVjktRDFVZTFpX19ka0ZJbDB5MnBBMkl4VXlRcDZiQjBwQ2FXdXlkQkdaMFhSSi1KYlhWb3FDZDZaQ3p6V0wtdENZV3VEMk5pVUZLTl9HYkswX3J1T1VMMGxIOGJ6R0JEODVMbGMxSU01SjZ0ZHR0cUN3?oc=5","date":"2024-12-25","type":"trial","source":"prnewswire.com","summary":"Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting - prnewswire.com","headline":"Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveile","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNLVphSUYyb19XalJIeTdKb3VJRmFCN1F3ZUVtMGhaeFozR3B2THRsblQyYW1zcjFfSVZWMXRmRGtSVmdRSmxzV3FHNXV1amVFWE5VcVhmUlBzMWhPQUhhUVlCbkxkZEk5MTBMUzg4MEFLV1NrTGpqbEtqbHNuRmZGclZDNVgwQS12YlNoNkUwMnJoandxZmFXOGlWcml0dWlSYWsweVVPSnJKaG1kOFU1MnV2NkQwXzM0b3EzQV9uSTliY1ZsZW1OMkRncjJUS21fSmd3?oc=5","date":"2024-06-05","type":"patent","source":"Reuters","summary":"Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic - Reuters","headline":"Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPSFNQM1J5MF9ZbDM3b3BlU2duQU0xYkY1dzIweWVKYjFab2dMOUVmUjkxb3BCQVRpcnBnWXBxR2JGUkFMaHY2SHF4ek5oVHZ4QU41a2dBRXBhSGZ1UkhzVHk4T2ZyLVI4WFo1UDIzdDNoRGV4UjRIVTI1Zkl6bVVSSlZNWjd4LXRCR1g3anBLOVBXR01ZMUE?oc=5","date":"2023-07-02","type":"pipeline","source":"Yahoo Finance","summary":"Chinese Company Qilu Pharmaceutical Is Supplying the Anti-Cancer Drug Cisplatin Injection to the United States Again - Yahoo Finance","headline":"Chinese Company Qilu Pharmaceutical Is Supplying the Anti-Cancer Drug Cisplatin Injection to the United States Again","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNOHdDQmsxNzFxVXBoQ2NKTXFxVzZ0eWo0SE8tU1ZsT0V3d0JtNTZPd0VacEpzX3BBbmFvRGg4XzlwdVRsa3k3Rk40aFYxM2hKb3U1RDNnQ2NVYThlbTUzaXVPQnJIR3FhT0hEX0lsX01IZ09CTURaQmpCYy1xZXZBWVFXVmJ2NS1KOEJFQVpyTU9UdWxNcTZNVTgwSDVxWkJ5TjhwTjRfYnZ2SnB1VGhMOWNOUQ?oc=5","date":"2022-09-05","type":"pipeline","source":"labiotech.eu","summary":"CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy - labiotech.eu","headline":"CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy","sentiment":"neutral"}],"patents":[],"drugCount":54,"phaseCounts":{"phase_3":41,"phase_2":3,"phase_1":3,"marketed":7},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}